Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Females with age between 18 and 70 years old~2. Histological proven unresectable recurrent or advanced breast cancer~3. Triple-negative for estrogen receptor (ER), progestogen receptor (PR), and human epithelial receptor-2 (HER2) by immunohistochemistry (IHC) test. For patients with ER negative, PR negative, Her2 two plus, a negative Her2 gene amplification should be verified with FISH test. Her2 one plus may consider FISH verification.~4. No prior chemotherapy for metastatic breast cancer. Prior use of taxanes in the adjuvant/neoadjuvant setting is acceptable if completed 6 months prior to enrollment~5. At least one measurable disease according to the response evaluation criteria in solid tumor (RECIST)~6. Performance status not more than 1~7. All patients enrolled are required to have adequate hematologic, hepatic, and renal function~8. Life expectancy greater than 12 weeks~9. No serious medical history of heart, lung, liver and kidney~10. Provision of written informed consent prior to any study specific procedures~11. Patients with good compliance~Exclusion Criteria:~1. Pregnant or lactating women (female patients of child-bearing potential must have a negative serum pregnancy test within 14 days of first day of drug dosing, or, if positive, a pregnancy ruled out by ultrasound)~2. Women of child-bearing potential, unwilling to use adequate contraceptive protection during the course of the study~3. Treatment with radiotherapy at the axial skeleton within 4 weeks before the first treatment or has not recovered from all toxicities of previously administered radiotherapy~4. Treatment with an investigational product within 4 weeks before the first treatment~5. Symptomatic central nervous system metastases, except for patients with stable and asymptomatic brain metastases who have completed a course of cranial irradiation, and have at least one measurable lesion outside the brain. Radiotherapy should be completed within 4 weeks prior to the registration~6. Other active malignancies (including other hematologic malignancies) or other malignancies within the last 5 years, except for cured nonmelanoma skin cancer or cervical intraepithelial neoplasia.~7. Patient having a history of clinically significant cardiovascular, hepatic, respiratory or renal diseases, clinically significant hematological and endocrinal abnormalities, clinically significant neurological or psychiatric conditions~8. Uncontrolled serious infection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Gemcitabine,cisplatin (Type: EXPERIMENTAL): GP (gemcitabine and cisplatin)
- Gemcitabine, Paclitaxel (Type: ACTIVE_COMPARATOR): GT (gemcitabine and paclitaxel combination)

Based on this trial design, predict the completion outcome and termination type (if applicable).